Maravai LifeSciences Holdings Inc
NASDAQ:MRVI
Income Statement
Earnings Waterfall
Maravai LifeSciences Holdings Inc
Revenue
|
288.9m
USD
|
Cost of Revenue
|
-148.7m
USD
|
Gross Profit
|
140.2m
USD
|
Operating Expenses
|
-165.4m
USD
|
Operating Income
|
-25.2m
USD
|
Other Expenses
|
-93.8m
USD
|
Net Income
|
-119m
USD
|
Income Statement
Maravai LifeSciences Holdings Inc
Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||
Revenue |
464
N/A
|
669
+44%
|
799
+19%
|
895
+12%
|
920
+3%
|
907
-1%
|
883
-3%
|
718
-19%
|
544
-24%
|
420
-23%
|
289
-31%
|
|
Gross Profit | ||||||||||||
Cost of Revenue |
(93)
|
(125)
|
(141)
|
(151)
|
(150)
|
(156)
|
(169)
|
(163)
|
(169)
|
(167)
|
(149)
|
|
Gross Profit |
372
N/A
|
544
+46%
|
659
+21%
|
745
+13%
|
770
+3%
|
750
-3%
|
714
-5%
|
555
-22%
|
376
-32%
|
253
-33%
|
140
-44%
|
|
Operating Income | ||||||||||||
Operating Expenses |
(96)
|
(124)
|
(115)
|
(129)
|
(127)
|
(134)
|
(140)
|
(146)
|
(158)
|
(168)
|
(165)
|
|
Selling, General & Administrative |
(86)
|
(111)
|
(100)
|
(108)
|
(112)
|
(118)
|
(129)
|
(133)
|
(140)
|
(148)
|
(151)
|
|
Research & Development |
(4)
|
(6)
|
(9)
|
(16)
|
(19)
|
(22)
|
(16)
|
(18)
|
(18)
|
(17)
|
(15)
|
|
Depreciation & Amortization |
(6)
|
(7)
|
(6)
|
(5)
|
(4)
|
(3)
|
(3)
|
(3)
|
(3)
|
(3)
|
(3)
|
|
Other Operating Expenses |
0
|
0
|
0
|
0
|
8
|
8
|
8
|
8
|
2
|
(0)
|
3
|
|
Operating Income |
276
N/A
|
420
+52%
|
543
+29%
|
616
+13%
|
643
+4%
|
616
-4%
|
574
-7%
|
409
-29%
|
217
-47%
|
85
-61%
|
(25)
N/A
|
|
Pre-Tax Income | ||||||||||||
Interest Income Expense |
(24)
|
(32)
|
(30)
|
(22)
|
(19)
|
(15)
|
(18)
|
(21)
|
(17)
|
(18)
|
(18)
|
|
Non-Reccuring Items |
(8)
|
4
|
11
|
11
|
11
|
(0)
|
(0)
|
0
|
0
|
0
|
(6)
|
|
Total Other Income |
6
|
9
|
6
|
3
|
2
|
(2)
|
(5)
|
(8)
|
(8)
|
(9)
|
668
|
|
Pre-Tax Income |
250
N/A
|
401
+60%
|
531
+32%
|
608
+14%
|
637
+5%
|
599
-6%
|
552
-8%
|
380
-31%
|
192
-50%
|
57
-70%
|
618
+976%
|
|
Net Income | ||||||||||||
Tax Provision |
(26)
|
(44)
|
(62)
|
(68)
|
(75)
|
(70)
|
(61)
|
(38)
|
(18)
|
2
|
(756)
|
|
Income from Continuing Operations |
225
|
357
|
469
|
540
|
562
|
530
|
491
|
343
|
174
|
59
|
(138)
|
|
Income to Minority Interest |
(129)
|
(207)
|
(287)
|
(314)
|
(315)
|
(292)
|
(271)
|
(189)
|
(98)
|
(35)
|
19
|
|
Net Income (Common) |
96
N/A
|
150
+56%
|
182
+22%
|
225
+24%
|
248
+10%
|
238
-4%
|
220
-7%
|
153
-30%
|
76
-51%
|
25
-68%
|
(119)
N/A
|
|
EPS (Diluted) |
0.22
N/A
|
0.57
+159%
|
0.7
+23%
|
0.88
+26%
|
1.84
+109%
|
1.8
-2%
|
0.86
-52%
|
1.16
+35%
|
0.57
-51%
|
0.18
-68%
|
-0.9
N/A
|